Tag: CDTI

Blue Horseshoe Stocks: ACRX, DSCO & More

Tesla Motors, Inc. TSLA – Options

Yesterday, those of our readers following our recent coverage of TSLA were once again presented with opportunities coming out of the 05/22 $230-240 Calls that we’ve been monitoring since Friday. TSLA registered a higher high and a higher low for the fifth consecutive session, topping out at 248.30. As a result, the total possible gains on our initial calls were pushed even further into the green, so we wanted to provide an update on those figures:

$230 Calls  – Friday’s Low: 6.85 – Yesterday’s High: 17.95 – Max Gain: 162%

$232.50 Calls  – Friday’s Low: 5.32 – Yesterday’s High: 16.90 – Max Gain: 217%

$235 Calls  – Friday’s Low: 5.96 – Yesterday’s High: 13.95 – Max Gain: 134%

$237.50 Calls  – Friday’s Low: 3.16 – Yesterday’s High: 12.00  – Max Gain: 280%

$240 Calls  – Friday’s Low: 3.84 – Yesterday’s High: 10.50 – Max Gain: 173%

These moves are a perfect example of what draws us to options trading; with just a 6% increase in TSLA stock, we’ve witnessed huge gains across the board in the options chain. These contracts don’t expire until next Friday, so we’ll keep our fingers on TSLA’s pulse until that time.

AcelRx Pharmaceuticals, Inc. ACRX

Popping up on our scanner this morning is a play that has both an interesting chart as well as a blockbuster PR out today that is leading to a gap-up in premarket trading (3.30-3.80’s).

We’re catching the stock as it comes up off of a relative bottom, and as we point out on the snapshot below, there are several attractive features of the current ACRX chart.

Couple that with this morning’s revelation of a contract the company has struck with the US Dept. of Defense, and ACRX becomes instantly worthy of our attention as the week draws to a close.

Discovery Laboratories, Inc. DSCO

Speaking of pharma stocks with fresh news, DCSO is also cropping up on our scanner this morning. Like the aforementioned play, this morning/s PR is resulting in a gap-up, and we’ll want to have our eyes peeled for potential advantageous activity on the chart once the session commences.

According to the release, Phase II testing of its AEROSURF® product has yielded “encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome”

Extended Watchlist:
PTBI, CYRN, BAA, CDTI, WOGI

Blue Horseshoe Stocks: ICLD Update & More

InterCloud Systems, Inc. ICLD

We’ve been tracking ICLD continuously since last Monday, and after witnessing a low of 3.01 and subsequent run to 4.30 that day (+43%), the stock turned in quite an admirable performance for the week as a whole.

Following a dip back to 3.01 on Tuesday, ICLD would register higher highs and higher lows all week, which provided some excellent swing-trade opportunities. Tuesday’s intraday run carried ICLD in a range from 3.01-4.00, for chances at up to 33% in gains. On Wednesday the move was from 3.11-3.75 (21%). Thursday’s session brought a similar 22% gain as it pushed from 3.35 to 4.09.

The great weekly performance culminated in a new high being set on Friday as the stock touched a low of 3.65 before reaching 4.48. It marked another nice intraday spike (+23%) and an overall increase of 49% over our observed low earlier in the week.

The stock has traded up to the 4.30’s here in the premarket, so we’ll have ICLD on our watchlist as we kick off a new trading week, and we’ll be interested to follow the action. We’ll also remind our readers that the company has a conference call scheduled for Wednesday, the info for which you can obtain by clicking through the link to the PR below.

SHREWSBURY, N.J., May 8, 2015 (GLOBE NEWSWIRE) — InterCloud Systems, Inc. (ICLD) (“InterCloud” or the “Company”), a single-source provider of end-to-end information technology (IT) and next-generation network solutions, to the service provider (carrier) and corporate enterprise markets, through cloud solutions and professional services will hold a conference call to discuss its financial results for the First Quarter 2015. CEO Mark Munro and CFO Tim Larkin will participate in the call >> FULL PR

Extended Watchlist:
CDTI (News), CANF, CERE, VGGL, RXII

Blue Horseshoe Stocks: NYMX Update, LTNC & More

Nymox Pharmaceutical Corp. NYMX

We certainly hope our readers read over yesterday’s morning report thoroughly, because it would mean that people caught our closing note on NYMX in the extended watchlist. We mentioned the big gap-down on the stock, and that we’d be on the lookout for a reversal.

It didn’t take any time at all for NYMX to behave according to our suspicions; it opened at a low of .59 and immediately began its recovery, which lasted for a good portion of the day and culminated in a high of 1.03. Big congratulations are in order for anyone that took advantage of that 74% intraday rip.

The huge gap-down was apparently caused from a knee-jerk reaction to Sunday’s announcement that the company’s prostate cancer treatment (NX-1207) failed to meet primary efficacy endpoints in Phase 3 studies.

It’s fair to mention that prior to yesterday’s session, NYMX was trading at a base level just below $5 (50DMA of 4.77) and yesterday’s bottom-bounce carried it back up to a mere fraction of that level, so it will be interesting to see how much of its lost ground could potentially be recovered in coming sessions.

Labor Smart Inc. LTNC

We caught LTNC on a routine news scan this morning, and we really like what we learned from a quick glance at the PR. LTNC announced that its October revenues set a company record ($2.7M), contributed to a 23-month streak of year-over-year increases, and brought total revenue for 2014 over the $20M-mark.

Those highlights are substantial enough to have us put LTNC on our radar moving forward. A company exhibiting growth patterns like these is certainly worth watching.

The chart is also coming off of a relative bottom, so it could be that we’ve stumbled across LTNC at just the right time.

Extended Watchlist:
CDTI, CDVI, ODP, VSR, MWW, FCEL